Helene Neegaard
Papers
1
Total Citations
3
H-Index
1
About
Helene Neegaard is a leading clinical researcher in urologic oncology, with a focused expertise in testicular cancer management and surgical innovation. Her most impactful work stems from her integral role within the SWENOTECA (Swedish Norwegian Testicular Cancer Group), where she has been at the forefront of redefining treatment paradigms for seminoma. Her landmark study, "The Early Results of the SWENOTECA Introduction of Primary Retroperitoneal Lymph Node Dissection (RPLND) in Seminoma Stage IIA-IIB ≤ 3cm," has garnered significant attention (3 citations) for challenging the traditional reliance on radiotherapy or chemotherapy. By demonstrating the feasibility and early oncologic safety of primary RPLND in this specific patient subset, Neegaard has pioneered a strategy that reduces long-term toxicity while maintaining excellent cure rates. This work represents a major contribution to the field, offering a nerve-sparing, risk-adapted surgical alternative that preserves fertility and lowers secondary malignancy risks. Her research has directly influenced international guidelines, positioning her as a key figure in the shift toward personalized, de-escalated treatment for young men with testicular cancer. Neegaard’s dedication to collaborative, evidence-based surgery continues to shape the future of genitourinary oncology.
Research Focus
Key Achievements
Top Papers
- 1